{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:19:14Z","timestamp":1783448354316,"version":"3.55.0"},"reference-count":23,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":110,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>A better understanding of the benefit of burosumab for treating tumor-induced osteomalacia (TIO) in Chinese patients is needed. The objective of this open-label, multicenter, single-cohort, post-marketing phase 4 study was to assess the efficacy, pharmacokinetics, pharmacodynamics, and safety of burosumab after repeated administration in Chinese adults with TIO. Burosumab was administered subcutaneously every 4 weeks for up to 48 weeks at an initial 0.3 mg\/kg dose. We investigated the change from baseline in mean serum phosphorus level over time and changes in serum and urinary phosphorus levels, bone turnover biomarkers, patient-reported outcomes, and other parameters after repeated burosumab administration. Nine patients were treated. Serum phosphorus levels increased and remained above baseline and lower limit of normal at the end of the dosing cycles (averaged over weeks 20\u201348) (mean (standard deviation) change, 1.5 (0.86) mg\/dL). Tubular reabsorption of phosphate and the ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate increased and remained above baseline values. Alkaline phosphatase (ALP), bone-specific ALP, carboxy-terminal cross-linked telopeptide of type I collagen, and procollagen type 1 N-terminal propeptide levels increased, reaching maximums at weeks 16 or 24. The distance walked in 6 min nearly doubled from baseline by week 48. Patients reported improvements in pain and quality of life over time. There were no serious adverse events and only five treatment-related adverse events (all mild in severity) in three patients. In Chinese patients with TIO, continued treatment with burosumab can provide sustained clinical benefit and a favorable safety profile.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>Clinical trial registration<\/jats:title>\n                      <jats:p>ClinicalTrials.gov (NCT05357573).<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0601","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:03:57Z","timestamp":1772028237000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Burosumab for adults with tumor-induced osteomalacia in China"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3796-8440","authenticated-orcid":true,"given":"Ruizhi","family":"Jiajue","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Lu","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemei","family":"Gu","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinwei","family":"Yung","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kuriki","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-1617","authenticated-orcid":true,"given":"Zhenlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":true,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026070714064986200_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1507\/endocrj.EJ15-0289","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2013proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society","volume":"62","author":"Fukumoto","year":"2015","journal-title":"Endocr J"},{"key":"2026070714064986200_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314896","article-title":"Osteomalacia is not a single disease","volume":"23","author":"Cianferotti","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026070714064986200_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ecl.2010.02.001","article-title":"Osteomalacia as a result of vitamin D deficiency","volume":"39","author":"Bhan","year":"2010","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2026070714064986200_bib4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"key":"2026070714064986200_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12957-015-0763-7","article-title":"Tumour-induced osteomalacia: a literature review and a case report","volume":"14","author":"Dadoniene","year":"2016","journal-title":"World J Surg Oncol"},{"key":"2026070714064986200_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026070714064986200_bib8","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/jbmr.4331","article-title":"Early discrimination between tumor-induced rickets\/osteomalacia and X-linked hypophosphatemia in Chinese children and adolescents: a retrospective case-control study","volume":"36","author":"Jiajue","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10580","article-title":"Rare diseases that impersonate one another: X-linked hypophosphatemia and tumor-induced osteomalacia, a retrospective analysis of discriminating features","volume":"6","author":"DeCorte","year":"2022","journal-title":"JBMR Plus"},{"key":"2026070714064986200_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","article-title":"Reports of 17 Chinese patients with tumor-induced osteomalacia","volume":"35","author":"Yu","year":"2017","journal-title":"J Bone Miner Metabol"},{"key":"2026070714064986200_bib11","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1210\/jc.2005-2105","article-title":"Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia","volume":"91","author":"Imel","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714064986200_bib12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"key":"2026070714064986200_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"2026070714064986200_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070714064986200_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib18","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070714064986200_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2026070714064986200_bib20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"2026070714064986200_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2026070714064986200_bib22","volume-title":"2016 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR); Atlanta, GA, USA; September 16\u201319 2016","author":"Carpenter","year":"2023"},{"key":"2026070714064986200_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/3\/EC-25-0601.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/3\/EC-25-0601.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0601\/504636\/ec-25-0601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0601\/504636\/ec-25-0601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:06:55Z","timestamp":1783447615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/3\/e250601\/75847\/Burosumab-for-adults-with-tumor-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0601","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"e250601"}}